[{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"1b4e994d-52e1-4f2a-9230-cf391cb47aea","acronym":"NCI-2023-03572","url":"https://clinicaltrials.gov/study/NCT06034470","created_at":"2023-09-13T14:09:48.343Z","updated_at":"2025-02-25T17:02:50.246Z","phase":"Phase 1","brief_title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT06034470 - NCI-2023-03572","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" Chr t(15;17)","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-03"},{"id":"9263296a-f501-4dcf-9d13-ddd3f6920a7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320380","created_at":"2023-08-14T10:11:08.231Z","updated_at":"2024-07-02T16:35:38.286Z","phase":"Phase 1/2","brief_title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","source_id_and_acronym":"NCT05320380","lead_sponsor":"Children's Oncology Group","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-09-01"},{"id":"7c0994a9-8277-4f13-b963-37bb1082d426","acronym":"CADENZA","url":"https://clinicaltrials.gov/study/NCT03386513","created_at":"2023-08-14T10:10:58.304Z","updated_at":"2024-07-02T16:35:41.144Z","phase":"Phase 1/2","brief_title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","source_id_and_acronym":"NCT03386513 - CADENZA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-03"}]